Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics Inc.verified

IMDX

Price:

$4.91

Market Cap:

$140.74M

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Dete...[Read more]

Industry

Biotechnology

IPO Date

2015-12-30

Stock Exchange

NASDAQ

Ticker

IMDX

The Enterprise Value as of March 2026 (TTM) for Insight Molecular Diagnostics Inc. (IMDX) is 125.18M

According to Insight Molecular Diagnostics Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 125.18M. This represents a change of 97.09% compared to the average of 63.51M of the last 4 quarters.

Insight Molecular Diagnostics Inc. (IMDX) Historical Enterprise Value (quarterly & annually)

How has IMDX Enterprise Value performed in the past?

The mean historical Enterprise Value of Insight Molecular Diagnostics Inc. over the last ten years is 96.29M. The current 125.18M Enterprise Value has changed 12.90% with respect to the historical average. Over the past ten years (40 quarters), IMDX's Enterprise Value was at its highest in in the June 2021 quarter at 475.41M. The Enterprise Value was at its lowest in in the December 2023 quarter at 14.09M.

Quarterly (TTM)
Annual

Average

96.29M

Median

111.41M

Minimum

12.56M

Maximum

177.37M

Insight Molecular Diagnostics Inc. (IMDX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Insight Molecular Diagnostics Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 116.71%

Maximum Annual Enterprise Value = 177.37M

Minimum Annual Increase = -88.46%

Minimum Annual Enterprise Value = 12.56M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202426.14M108.02%
202312.56M-34.28%
202219.12M-88.46%
2021165.69M4.88%
2020157.98M58.76%
201999.51M116.71%
201845.92M-66.06%
2017135.30M-23.72%
2016177.37M43.84%
2015123.31M-32.15%

Insight Molecular Diagnostics Inc. (IMDX) Average Enterprise Value

How has IMDX Enterprise Value performed in the past?

The current Enterprise Value of Insight Molecular Diagnostics Inc. (IMDX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

19.27M

5-year avg

76.30M

10-year avg

96.29M

Insight Molecular Diagnostics Inc. (IMDX) Enterprise Value vs. Peers

How is IMDX’s Enterprise Value compared to its peers?

Insight Molecular Diagnostics Inc.’s Enterprise Value is less than C4 Therapeutics, Inc. (210.67M), less than Sangamo Therapeutics, Inc. (135.47M), greater than Cybin Inc. (-70774799.20), less than OmniAb, Inc. (198.54M), greater than Prelude Therapeutics Incorporated (115.91M), less than Codexis, Inc. (167.84M), less than Armata Pharmaceuticals, Inc. (546.65M), greater than Invivyd, Inc. (6.75M), less than PepGen Inc. (324.53M), less than Milestone Pharmaceuticals Inc. (155.31M),

CompanyEnterprise ValueMarket cap
210.67M$225.29M
135.47M$140.57M
-70774799.20$413.02M
198.54M$203.73M
115.91M$183.90M
167.84M$145.42M
546.65M$383.73M
6.75M$230.95M
324.53M$368.04M
155.31M$144.79M

Build a custom stock screener for Insight Molecular Diagnostics Inc. (IMDX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Insight Molecular Diagnostics Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Insight Molecular Diagnostics Inc. (IMDX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Insight Molecular Diagnostics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Insight Molecular Diagnostics Inc.'s Enterprise Value?

What is the highest Enterprise Value for Insight Molecular Diagnostics Inc. (IMDX)?

What is the 3-year average Enterprise Value for Insight Molecular Diagnostics Inc. (IMDX)?

What is the 5-year average Enterprise Value for Insight Molecular Diagnostics Inc. (IMDX)?

How does the current Enterprise Value for Insight Molecular Diagnostics Inc. (IMDX) compare to its historical average?